与Apolipoprotein E的联合聚合调节了阿尔茨海默氏病中amyloid-β的功能
Zengjie Xia1,2, Emily E Prescott3, Agnieszka Urbanek3
1Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK.
Nature communications
|June 1, 2024
概括
遗传的阿波利波蛋白E (apoE) 异型通过调节粉样β (Aβ) 聚合,影响阿尔茨海默病 (AD) 风险. 准apoE-Aβ相互作用为AD提供了一个治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 生物化学 生物化学
背景情况:
- 遗传的阿波利波蛋白E (apoE) 异型是晚发性阿尔茨海默病 (AD) 的关键遗传风险因素.
- 通过apoE影响AD病变的确切机制,特别是它与粉样β (Aβ) 的直接相互作用,仍然不完全理解.
研究的目的:
- 在聚合过程中调查apoE异型和Aβ之间的动态相互作用.
- 阐明这些相互作用如何调节Aβ与疾病相关的功能,并导致AD风险.
- 探索向apoE-Aβ联合聚合物的治疗潜力.
主要方法:
- 单分子成像以实时观察apoE和Aβ相互作用.
- 在人类大脑组织中对Aβ聚合物的生物化学分析.
- 评估针对性干预措施的Aβ清除,炎症标志物和膜损伤.
主要成果:
- 所有的apoE异型在早期的聚合阶段与Aβ结合,在纤维形成时解离.
- 在具有高风险APOE4基因型的个体中,ApoE-Aβ联合聚合物构成了可扩散Aβ的很大一部分.
- 动态的apoE-Aβ相互作用以异型和脂化特异的方式调节Aβ聚合,清除和毒性.
结论:
- 遗传的apoE基因型通过Aβ的异型特异调节影响AD风险.
- 向和去除非脂质的apoE4-Aβ联合聚合物可以增强质细胞对Aβ的清除.
- 通过向这些协同聚合物来减少炎症和膜损伤,为AD提供了一个有希望的治疗途径.
相关概念视频
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179